- Article
- Source: Campus Sanofi
SCORE-AD-Calculator
SCORE-AD Calculator & Atopic Dermatitis Assessment Tools for Healthcare Professionals. Access validated severity scales including SCORAD, EASI, vIGA-AD, DLQI, and POEM to evaluate disease severity, patient outcomes, and quality of life in one platform.
Calculate and Record the Severity of Your Patients with Atopic Dermatitis
SCORE-AD — All-in-One Assessment Platform
With the SCORE-AD calculator, calculate and record the severity of your patients with Atopic Dermatitis. Check in one place the different validated skin scales for patients with AD and easily assess disease severity, patient-reported outcomes, and quality of life.
Clinician-Assessed Severity Scales
1. SCORE-AD — SCORing Atopic Dermatitis
Score range: 0–103
Composite validated tool combining: A. Extent (BSA affected). B. Intensity (6 clinical signs: erythema, edema/papules, oozing/crusting, excoriation, lichenification, dryness). C. Patient-reported pruritus and sleep disturbance.
|
Severity |
Mild |
Moderate |
Severe |
| SCORAD | < 25 | 25–50 | > 50 |
2. EASI — Eczema Area and Severity Index
Score range: 0–72
Clinician-assessed extent and severity across 4 body regions. Key response thresholds: EASI-50 / EASI-75 / EASI-90 (50%, 75%, 90% improvement from baseline).
|
Severity |
Mild |
Moderate |
Severe |
| EASI | < 8 | 8–21 | > 21 |
3. vIGA-AD — Validated Investigator's Global Assessment
Score range: 0–4
5-point global severity scale. Treatment response: vIGA-AD 0 or 1 with ≥2-point reduction from baseline.
|
0 |
1 |
2 |
3 |
4 |
| Clear | Almost clear | Mild | Moderate | Severe |
Patient-Reported Outcome Scales
4. DLQI — Dermatology Life Quality Index
Score range: 0–30
10-item QoL questionnaire assessing impact of skin disease over the past week.
|
0–1 |
2–5 |
6–10 |
11–20 |
21–30 |
| No effect | Small | Moderate | Very large | Extremely large |
5. Pruritus NRS — Numerical Rating Scale for Itch
Score range: 0–10
Patient-reported worst itch intensity in the past 24 hours.
|
0 |
1–3 |
4–7 |
≥ 8 |
| No itch | Mild | Moderate | Severe |
6. POEM — Patient-Oriented Eczema Measure
Score range: 0–28
7-item questionnaire on symptom frequency over the past week (dryness, itch, flaking, cracking, sleep loss, bleeding, weeping).
|
0–2 |
3–7 |
8–16 |
17–24 |
25–28 |
| Clear | Mild | Moderate | Severe | Very severe |
7. ADCT — Atopic Dermatitis Control Tool
The ADCT gives a measure of how controlled eczema is. Answer these 6 simple questions with your patient to find the ADCT score, it will indicate the appropriate course of action.
- Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186(1):23–31.
- Gooderham MJ, et al. Approach for the assessment and management of adult patients with atopic dermatitis. J Cutan Med Surg. 2018;22(1_suppl):10S–16S.
- Taïeb A. Atopic dermatitis: definition, epidemiology, natural history, severity and scores. Ann Dermatol Venereol. 2005;132 Spec No. 1:1S35–43.
- Wollenberg A, et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol. 2016;30:729–47.
- Charman CR, et al. The patient-oriented eczema measure: development and initial validation. Arch Dermatol. 2004;140(12):1513–9.
- Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI). Clin Exp Dermatol. 1994;19(3):210–6.
- Schram ME, et al. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol. 2011;128(2):353–9.
- Wollenberg A, et al. Consensus-based European guidelines for treatment of atopic eczema: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682.
For Healthcare Professionals Only
Please log in or register to continue reading.
Atopic Dermatitis: Disease Modification in Focus
Curated evidence on atopic dermatitis, organised around the four disease-modification pillars — starting with new data on skin-barrier restoration in children.
Atopic Dermatitis: Disease Modification in Focus
Curated June evidence on atopic dermatitis, organised around the four disease-modification pillars — starting with new data on skin-barrier restoration in children
Attenuating the atopic march: Meta Analysis of The Dupilumab Atopic Dermatitis Database for Incident Allergic Events
Learn morePatient-Video
Request-form
